In addition, new research in metabolic diseases contributed to higher research costs in the first quarter of 2001. Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs that act through the regulation of gene expression. Tularik programs address cancer, viral diseases, inflammation, immune disorders, lipid disorders, diabetes, bacterial diseases and obesity. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Derived from audited consolidated financial statements at that date.
Press releases are only accurate as of their respective dates.
Tularik does not undertake to update this information included in any press release.